Inicio・Lista de Acciones・Gossamer Bio Inc

Gossamer Bio Inc

Cerrado

SectorSanidad

0.17 -5.56

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

0.17

Máximo

0.18

Métricas clave
By Trading Economics
Ingresos	574K -47M
Ventas	3.2M 17M
BPA	-0.2
Margen de beneficios	-275.223
Empleados	161
EBITDA	2.1M -44M

Recomendaciones
By TipRanks
Recomendaciones	Neutral
Estimación a 12 Meses	+494.44% upside

Dividendos
By Acuity
Próximas Ganancias	17 ago 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	5.4M 85M
Apertura anterior	5.73
Cierre anterior	0.17

Noticias sobre sentimiento de mercado

By Acuity

61%

39%

269 / 340 Clasificación en Healthcare

Gossamer Bio Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

7 ago 2026, 19:56 UTC

Gossamer Bio Inc shares are higher today amid a weaker jobs report, easing interest rate hike concerns and shifting market sentiment towards a dovish outlook.

6 ago 2026, 23:12 UTC

Gossamer Bio Inc. shares are effectively unchanged in after-market trading, remaining flat within a narrow band. The stock is above its 20-day moving average.

5 ago 2026, 23:36 UTC

Gossamer Bio Inc shares are higher in after-market trading, despite no specific news. The stock is also above its 20-day moving average.

4 ago 2026, 23:01 UTC

Gossamer Bio shares declined after-market, reflecting broader market trends amid falling crude oil prices. Volatility was noted with fluctuations in trading.

3 ago 2026, 23:06 UTC

Gossamer Bio Inc. shares remained roughly flat in after-market hours, with no specific news identified. Broader market sentiment improved following strong manufacturing data.

1 ago 2026, 00:02 UTC

Social Media

Gossamer Bio Inc shares are lower in after-market hours, continuing a downward trend following recent gains tied to an FDA update on Seralutinib.

31 jul 2026, 23:41 UTC

Social Media

Gossamer Bio Inc. shares are higher in after-market trading following an FDA update on Seralutinib, its candidate for pulmonary arterial hypertension.

30 jul 2026, 23:02 UTC

Gossamer Bio Inc is higher in after-market hours, reflecting broader market gains. The stock benefits from positive sentiment in the biotech sector.

29 jul 2026, 22:31 UTC

Gossamer Bio Inc. shares declined in after-market hours, reflecting unusual movement despite being above its 20-day moving average and near a one-month range high.

28 jul 2026, 23:41 UTC

Gossamer Bio Inc. shares are lower in after-market hours amid broader market declines, particularly in Asia's technology sector due to AI spending concerns.

27 jul 2026, 23:51 UTC

Social Media

Gossamer Bio Inc shares are higher in after-market trading following an upgrade to Outperform from Leerink and an FDA regulatory update on Seralutinib.

24 jul 2026, 22:01 UTC

Gossamer Bio Inc shares rose during after-market trading, reflecting notable strength despite mixed global equity market performance and without any specific company news identified.

23 jul 2026, 23:01 UTC

Gossamer Bio Inc's shares are higher in after-market trading, recovering from earlier losses despite no specific news to explain the movement.

22 jul 2026, 23:01 UTC

Gossamer Bio Inc shares are higher in after-market trading, reflecting a notable rise since Wednesday's close amid rising crude oil prices and geopolitical tensions.

21 jul 2026, 21:01 UTC

Gossamer Bio Inc shares are higher in after-market hours, buoyed by positive sentiment from better-than-expected second-quarter results across major companies.

20 jul 2026, 23:01 UTC

Gossamer Bio Inc shares are trading higher in after-market hours, despite no specific news, amid broader market volatility and inflation concerns.

Comparación entre iguales

Cambio de precio

Gossamer Bio Inc previsión

Precio Objetivo

By TipRanks

494.44% repunte

Estimación a 12 Meses

Media 1.07 USD 494.44%

Máximo 2 USD

Mínimo 0.28 USD

De acuerdo con 5 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Gossamer Bio Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

5 ratings

Comprar

Mantener

Vender

De acuerdo con 5 analistas que ofrecen calificaciones bursátiles a para Gossamer Bio Inc Dist en los últimos 3 meses.

Sentimiento

By Acuity

269 / 340 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Gossamer Bio Inc

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.